Malignant Melanoma Stage Iii clinical trials

Explore recruiting malignant melanoma stage iii clinical trials.

Recruiting malignant melanoma stage iii studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Malignant Melanoma Stage Iii trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

NeoLIPA: A multi center phase II open label study of neoadjuvant LTX-315 in combination with pembrolizumab in patients with clinically detectable and resectable stage III-IV melanoma

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients

Poland, Italy, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group

Portugal, Sweden, Poland, Finland, Netherlands, Spain +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.

Romania, Germany, Italy, Lithuania, France, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

CRISPR-TIL for metastatic melanoma

Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Malignant Melanoma Stage Iii trials by city

Malignant Melanoma Stage Iii in Toronto Malignant Melanoma Stage Iii in Vancouver Malignant Melanoma Stage Iii in Montreal Malignant Melanoma Stage Iii in Calgary Malignant Melanoma Stage Iii in Edmonton Malignant Melanoma Stage Iii in Ottawa Malignant Melanoma Stage Iii in Winnipeg Malignant Melanoma Stage Iii in Quebec City Malignant Melanoma Stage Iii in Hamilton Malignant Melanoma Stage Iii in Kitchener Malignant Melanoma Stage Iii in London Malignant Melanoma Stage Iii in Halifax Malignant Melanoma Stage Iii in New York Malignant Melanoma Stage Iii in Los Angeles Malignant Melanoma Stage Iii in Chicago Malignant Melanoma Stage Iii in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease